盟科药业(688373) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for the third quarter was ¥37,015,530.15, representing a year-on-year increase of 0.52%[4] - The total profit for the quarter was a loss of ¥54,848,430.68, with a cumulative loss of ¥193,407,150.71 for the year-to-date[4] - The net profit attributable to shareholders for the quarter was a loss of ¥54,861,654.71, with a year-to-date loss of ¥193,536,147.26[4] - Total operating revenue for the first three quarters of 2025 reached ¥103,985,283.24, an increase of 6.9% compared to ¥97,562,309.83 in the same period of 2024[20] - Net loss for the first three quarters of 2025 was ¥193,536,147.26, compared to a net loss of ¥291,296,145.99 in the same period of 2024, indicating an improvement of 33.6%[21] - The basic and diluted earnings per share for the quarter were both -¥0.08[5] - The basic and diluted earnings per share for the first three quarters of 2025 were both -¥0.30, an improvement from -¥0.44 in the same period of 2024[21] Research and Development - Research and development expenses totaled ¥56,333,880.25 for the quarter, a decrease of 27.85% compared to the previous year[5] - The ratio of R&D expenses to operating revenue was 152.19%, down 59.84 percentage points from the previous year[5] - Research and development expenses for the first three quarters of 2025 were ¥172,747,166.04, down from ¥244,246,074.92 in 2024, a decrease of 29.3%[20] Assets and Liabilities - Total assets at the end of the quarter were ¥726,934,188.94, a decrease of 14.39% from the end of the previous year[5] - Total current assets decreased from 748,661,957.20 RMB to 640,046,361.72 RMB, a decline of approximately 14.5%[15] - Total liabilities increased from 335,037,523.23 RMB to 400,211,748.73 RMB, an increase of approximately 19.5%[16] - The company reported a total of ¥2,366,460.10 in non-recurring gains and losses for the quarter[8] - The company's total liabilities increased to ¥469,380,110.62 from ¥410,164,907.91, an increase of 14.4%[20] - Total assets decreased from 849,128,659.62 RMB to 726,934,188.94 RMB, a decrease of about 14.4%[16] Cash Flow - Cash flow from operating activities showed a net outflow of ¥165,628,026.86, an improvement from a net outflow of ¥293,485,930.62 in the previous year[24] - Cash inflow from investment activities totaled ¥1,930,610,524.90, compared to ¥1,904,622,936.40 in the same period of 2024, reflecting a slight increase[24] - Cash inflow from financing activities was $91,702,238.69, down from $100,000,000.00, while cash outflow for financing activities increased to $37,650,658.55 from $26,070,254.51, resulting in a net cash flow from financing activities of $54,051,580.14, down from $73,929,745.49[25] - The net increase in cash and cash equivalents was $63,700,257.64, compared to $116,538,132.46 in the previous period, with an ending cash balance of $337,032,548.26, up from $254,014,785.61[25] - The impact of exchange rate changes on cash and cash equivalents was a decrease of $1,608,325.68, an improvement from a decrease of $3,394,068.68 in the prior period[25] Shareholder Information - Total number of common shareholders at the end of the reporting period is 16,492[12] - Genie Pharma holds 10.92% of shares, totaling 71,572,817 shares[12] - The company has no significant changes in the top ten shareholders or their shareholding status[13]